During a nearly 30 year career within the healthcare industry, most recently as the CEO of Philips Oral Diagnostics, David has driven transformational change within blue-chip and early stage companies. His broad knowledge base includes recent experience in personalized healthcare and nanotechnology.

A significant part of his career has been within blue-chip healthcare corporations, including Ortho Clinical Diagnostics (a Johnson and Johnson company), Kodak Clinical Diagnostics and Amersham International, where he focused on the development and commercialization of leading-edge systems in clinical diagnostics.

David's primary experience was gained as a Biomedical Scientist within the UK National Health Service, where he was involved in developing a wide range of innovative biomarker-based diagnostics across the full pathology spectrum, with particular emphasis on Chemical Pathology and Clinical Biochemistry.

In 2005, David established Oxonica Healthcare Ltd., a diagnostics company that specializes in the development and commercialization of advanced nanotechnology-based platforms for biomarker detection and personal care applications. During his tenure Oxonica acquired Mountain View, CA-based Nanoplex Technologies Inc. and entered into a co-development agreement with a Fortune 500 Company. He is currently focusing on the development and implementation of personalized healthcare solutions within Philips.

"We are very excited about David joining the biOasis team," says Rob Hutchison CEO. "The timing coincides with the Company's plans to move our p97-based diagnostic application for Alzheimer's disease from the research laboratory to a development phase where commercialization and global licensing are near to medium term goals. David's experience will be invaluable in guiding the biOasis team towards a variety of opportunities at this very exciting time in the company's growth.

"I am very excited to join the biOasis team," says David Browning. "Alzheimer's Disease is a significant and growing medical challenge for which the diagnostic and therapeutic product potential for biOasis's patented p97 technologies is enormous."

ABOUT BIOASIS:

biOasis Technologies Inc. is a Canadian Life Sciences company focused on the Health Care & Life Sciences market, and is engaged in the development and commercialization of diagnostics and therapeutic delivery systems related to neurological diseases.